Clinical trial · Observational
Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate safety and efficacy on Japanese subjects treated with nelarabine injection for intravenous use in clinical settings of the following diseases: 1. T-cell acute lymphocytic leukemia (T-ALL) 2. T-cell lymphoblastic lymphoma (T-LBL) Also, "any adverse events involving neurological disorder, hypotension, and blood disorder and their details" are to be investigated as an item of particular concern. In addition, subject outcome (alive or dead) at one year after the start of treatment will also be investigated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nelarabine | Drug | Nelarabine | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Subjects administered nelarabine
- description
- Subjects with T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) prescribed nelarabine during study period
- interventionNames
- Drug: Nelarabine
Primary outcomes (2)
- measure
- The number of adverse events in Japanese subjects treated with nelarabine based on prescribing information under the conditions of general clinical practice.
- timeFrame
- 1 year
- measure
- Any incidence of adverse events related to neurological disorder, hypotension, and blood disorder and their details
- timeFrame
- 1 year
Secondary outcomes (1)
- measure
- Outcome (alive or dead) at one year after the start of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) Exclusion Criteria: * Subjects with hypersensitivity to nelarabine
References
Publications (0)
Data not yet available